Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
CBL dec exp Erlotinib + Gemcitabine pancreatic ductal carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01621243 Phase Ib/II Gemcitabine + Nab-paclitaxel Necuparanib M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Terminated USA | CAN 0
NCT01821729 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Losartan Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer Unknown status USA 0
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Terminated USA 0
NCT02558894 Phase II Durvalumab Tremelimumab Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed USA | NLD | ESP | DEU | CAN 1
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT04177810 Phase II Cemiplimab + Plerixafor Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer Completed USA 0
NCT06400485 Phase I AMT-676 AMT-676 in Patients With Advanced Solid Tumors Recruiting AUS 1